Media ReleasesRadiopharm Theranostics

View All Radiopharm Theranostics News

Radiopharm Theranostics - Pilot Study Validates RAD Terbium-161 Radiotherapeutics

-- Publication of first head-to-head data shows superior Therapeutic Index with Tb161 vs Lu177 in 6 metastatic castration-resistant prostate cancer patients.
-- This Pilot study validates Radiopharm’s leadership in developing next generation Tb-161 radiotherapeutics for the treatment of advanced cancers.
-- Through partnership with TerThera, Radiopharm remains the first public company that disclosed a secured Tb-161 supply for the development of multiple programs.

Sydney, Australia – 28 February 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to share a recent publication by Schaefer-Schuler et al. on the results of 6 metastatic Castration-Resistant Prostate Cancer (mCRPC) patients treated with 161Tb vs 177Lu1.

The study demonstrated that 161Tb-PSMA-617 delivers markedly higher tumor-absorbed doses compared to 177Lu-PSMA-617, whereas the absorbed doses of the relevant organs at risk were only slightly higher. 161Tb-PSMA-617 delivered a radiation dose to tumor lesions that was on average 2.4 times higher than that of 177Lu-PSMA-617. This strongly supports Terbium-161 (Tb-161) as a promising candidate for use in the radiotherapeutic targeting of advanced cancers.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?